InMed Pharmaceuticals Inc. (INM) Financials
Annual revenue, profitability and per-share results for InMed Pharmaceuticals Inc., as reported in SEC filings.
Revenue • FY2026
$0
▼ 100.0%YoY
Net income • FY2026
-$12.56M
▼ 53.9%YoY
Diluted EPS • FY2026
$-3.12
▲ 62.7%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2026 | $0 | -$12.56M | — | $-3.12 | — | — | -100.0% |
| FY2025 | $4.94M | -$8.16M | $1.71M | $-8.36 | — | — | +7.5% |
| FY2024 | $4.6M | -$7.68M | $1.1M | $-1.01 | -$7M | — | +11.2% |
| FY2023 | $4.14M | -$7.95M | $1.4M | $-3.25 | -$7.44M | -192.2% | +202.8% |
Figures as reported in InMed Pharmaceuticals Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a INM filing.
Get an email when INM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.